Printer Friendly

Neurological Abnormality Could be the First and Only Symptom of Familial Hemophagocytic Lymphohistiocytosis: Report of Two Families.

Byline: Yun-Ze. Zhao, Hua. Cheng, Chang-Hong. Ding, Hong-Hao. Ma, Tong-Li. Han, Jiu-Wei. Li, Dong. Wang, Zhi-Gang. Li, Tian-You. Wang, Rui. Zhang

To the Editor: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease which impacts many parts of the body including the digestive, circulatory, and respiratory systems. The central nervous system (CNS) can also be affected, particularly in patients with familial HLH-2 (FHL-2), responsible for approximately 20% of all FHL. FHL-2 is a result of mutations to the perforin 1 ( PRF1 ) gene, which can occur at numerous sites on the gene.[1]

Studies demonstrate that CNS involvement, i.e., neurological symptoms, abnormal cranial magnetic resonance imaging (MRI), and/or cerebrospinal fluid (CSF), is indicators for a poor prognosis in HLH patients.[2] However, in some HLH patients, CNS impairment is the first and only symptom resulting in difficulties and delays for the diagnosis. Here, two HLH patients, who were initially misdiagnosed due to CNS impairment being the prominent clinical finding, are presented.

HLH was diagnosed after 5 months of investigations in a 3-year-old male patient. The patient suffered fevers, seizures, and vomiting and was diagnosed as encephalitis by the neurological department initially. Cranial MRI was performed and showed abnormal signals in his cerebral white-matter [Figure 1]a. The patients' serum EBV-DNA was elevated to 2.51 x 104 copies/ml and was given ganciclovir for antiviral treatment. Glucocorticoid was used to treat leukodystrophy. Three months later, the patient's cranial MRI showed that the lesion progressed significantly [Figure 1]b, and a whole-exome sequencing (WES) was performed. Five months after the first onset of the disease, he was referred to the hematology-oncology center. Since he suffered from fevers, seizures, hepatosplenomegaly, anemia, thrombocytopenia, hypertriglyceridemia, and hypofibrinogenemia, he was diagnosed with HLH. The WES showed PRF1 compound heterozygous mutations of c.1349G>A (p.T450M) and c.218C>T (p.C73Y), inherited from his father and mother, respectively. Unfortunately, the level of PRF1 was not determined before hematopoietic stem cell transplantation (HSCT). A retrospective review of the patient's history revealed that he had a small decrease in blood cell number (particularly neutrophils) and splenomegaly during fevers when he was treated in neurological department at the beginning. The patients' elder brother died of fevers, seizures, and vomiting at the age of 10 years, suggesting he might have had FHL-2. The HLH-2004 protocol was used for the treatment, and the patient had a partial remission after 4 weeks.[3] Intrathecal injection of dexamethasone and methotrexate was performed regularly. Two months after HLH-2004 treatment, HSCT was performed with a half-matched haploid donor. The lesion seen on the MRI significantly improved but did not disappear [Figure 1]c and [Figure 1]d. The patient appeared well at the last follow-up on June 30, 2018.{Figure 1}

A 6-year-old female patient was admitted to the neurological department on July 28, 2015, with a complaint of 'intermittent headaches, fevers, seizures, and unconsciousness for 2 days.' The patient had a Glasgow point of ten (eye-opening response: 4, verbal response: 2, and motion response: 4) with low muscular tension and negative pathologic reflex. An MRI showed extensive multifocal abnormal signaling in the gray matter, white matter, epencephalon, and brainstem [Figure 1]e, however, CSF was normal. The patient was diagnosed with acute disseminated encephalomyelitis and treated with immunotherapy including immunoglobulin and methylprednisolone. An MRI, at 4 months, showed that the lesions had progressed. The patient had a low neutrophil count, and splenomegaly was detected, although a bone marrow smear was normal. The patient was diagnosed with CNS demyelinating disease and treated with continuous immunotherapy. The patient's mouth dropped on the left after 1 month and was treated with immunotherapy periodically. The patient's MRI then improved [Figure 1]f. Eight months later, the patient had seizures, vomiting, hypodynamia, blurred vision, and speech difficulties, and an MRI revealed that the lesions had progressed [Figure 1]g. Mannitol and a high dose of methylprednisolone were administered, which controlled the clinical symptoms. At the same time, her 45-day-old brother was diagnosed with FHL-2 (fever, hemocytopenia, hepatosplenomegaly, hypertriglyceridemia, and hyperferritinemia), with compound heterozygous mutations of c.1349C>T (p. Thr450Met) and c.853_855del (p. 285del) on PRF1 . After an investigation, the same mutations were found in the female patient, and FHL-2 was confirmed. The level of PRF1 protein was low in both NK and CTL cells by 33% (normal range >81%) and below detection limits, respectively. Although the patient received intermittent immunotherapy, including methylprednisolone and immunoglobulin, HLH was diagnosed. The patient was treated using the HLH-2004 protocol,[3] and partial remission after 4 weeks occurred. Meanwhile, the original nidus seen in the MRI lessened but did not disappear [Figure 1]h. Although the patient and her brother could not afford HSCT, both were well on continuation treatment of HLH-2004 protocol. The last follow-up was on June 30, 2018.

These patients demonstrate that once a seizure occurs, MRI changes including abnormal signals in the white-matter demyelination and reduced blood cells during fever indicate CNS involvement, and HLH should be considered. Physical examination should be performed to identify hepatosplenomegaly. When necessary, transaminase, triglyceride, fibrinogen, ferritin, and solute IL-2R should be measured. WES is recommended for cases that relapse and progress after treatment. Early diagnosis is effective in increasing the survival.

Both patients had compound heterozygous mutations at the c.1349G>A (p.T450M) site, which is reported to be related to CNS disease in a Japanese study.[4] The c.218C>T (p.C73Y) in the second patient has not been reported previously, and little was known about it. Although c.853_855del (p.285del) is reported in the literature, its relationship with corresponding manifestations is unclear.[4] Future studies need to investigate whether these mutations can result in CNS involvement.

Overall, patients who have CNS symptoms and extensive white-matter abnormality in cranial MRI, combined with mildly decreased blood cells and splenomegaly during fever should be observed closely. Early diagnosis and prompt treatment can result in a better prognosis for patients who are prone to misdiagnosis of other neurological diseases such as leukodystrophy.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s)/patient's guardians has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the article. The patients/patient's guardians understand that their names and initials will not be published and due efforts will be made to conceal the identity of the patient, although anonymity cannot be guaranteed.

Financial support and sponsorship

This work was supported by the grants from the National Science and Technology Key Projects (No. 2017ZX09304029004), Beijing Municipal Science and Technology Commission (No. Z171100001017050), National Natural Science Foundation of China (No. 81700186, 81800189), Scientific Research Common Program of Beijing Municipal Commission of Education (No. KM201710025019), Talent Training Project-Fostering Fund of National Natural Science Foundation of Beijing Children's Hospital, Capital Medical University (No. GPY201713), The Special Fund of The Pediatric Medical Coordinated Development Center of Beijing Municipal Administration (XTZD20180202).

Conflicts of interest

There are no conflicts of interest.


1. Ishii E. Hemophagocytic lymphohistiocytosis in children: Pathogenesis and treatment. Front Pediatr 2016;4:47. doi: 10.3389/fped.2016.00047.

2. Zhao YZ, Zhang Q, Li ZG, Zhang L, Lian HY, Ma HH, et al. Central nervous system involvement in 179 Chinese children with hemophagocytic lymphohistiocytosis. Chin Med J 2018;131:1786-92. doi: 10.4103/0366-6999.237409.

3. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-31. doi: 10.1002/pbc.21039.

4. Ueda I, Kurokawa Y, Koike K, Ito S, Sakata A, Matsumora T, et al. Late-onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutations. Am J Hematol 2007;82:427-32. doi: 10.1002/ajh.20878.
COPYRIGHT 2018 Medknow Publications and Media Pvt. Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Correspondence
Author:Zhao, Yun-Ze; Cheng, Hua; Ding, Chang-Hong; Ma, Hong-Hao; Han, Tong-Li; Li, Jiu-Wei; Wang, Dong; Li,
Publication:Chinese Medical Journal
Article Type:Letter to the editor
Date:Dec 20, 2018
Previous Article:A Case of Male Primary Pulmonary Choriocarcinoma.
Next Article:Treatment of Adult Hirschsprung's Disease by Botulinum Toxin A through Anorectal Injection.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |